To examine whether R54high or B2high MLL/AF9-OVA leukemia cells, which were less sensitive to cytolysis by CTLs in vitro, preferentially survived in vivo in the presence of an adaptive immune response, we used immune-competent leukemia models that we developed recently [17] with some modifications. The gene discussed is MLLT3; the disease is leukemia.